ASH 2018 | CLARITY for CLL: ibrutinib/venetoclax achieve MRD negativity in R/R setting
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
The CLARITY study (ISCRTN13751862), part of the Bloodwise Trials Acceleration Programme (TAP), was the first clinical trial to investigate the combination of venetoclax and ibrutinib for relapsed/refractory chronic lymphocytic leukemia (CLL), with the aim of eradicating detectable disease and stopping treatment. Here,Talha Munir, MBBS, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, updates us on the results of the study; highlighting the tolerability, and high response and MRD eradication rates, in some cases leading to the cessation of therapy. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up